PubMed for Bookshelf ID: 5249030

Year	Number of Results
2020	3
2021	4
2022	1
2023	1
2024	0

1

Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.

Suppes T, Durgam S, Kozauer SG, Chen R, Lakkis HD, Davis RE, Satlin A, Vanover KE, Mates S, McIntyre RS, Tohen M. Suppes T, et al. Bipolar Disord. 2023 Sep;25(6):478-488. doi: 10.1111/bdi.13310. Epub 2023 Feb 26. Bipolar Disord. 2023. PMID: 36779257 Clinical Trial.

2

Lumateperone (Caplyta) for bipolar depression.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2022 Aug 8;64(1656):126-128. Med Lett Drugs Ther. 2022. PMID: 35921078 No abstract available.

3

Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.

Calabrese JR, Durgam S, Satlin A, Vanover KE, Davis RE, Chen R, Kozauer SG, Mates S, Sachs GS. Calabrese JR, et al. Am J Psychiatry. 2021 Dec;178(12):1098-1106. doi: 10.1176/appi.ajp.2021.20091339. Epub 2021 Sep 23. Am J Psychiatry. 2021. PMID: 34551584 Clinical Trial.

4

Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials.

Kane JM, Durgam S, Satlin A, Vanover KE, Chen R, Davis R, Mates S. Kane JM, et al. Int Clin Psychopharmacol. 2021 Sep 1;36(5):244-250. doi: 10.1097/YIC.0000000000000371. Int Clin Psychopharmacol. 2021. PMID: 34054112 Free PMC article.

5

Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia.

Correll CU, Vanover KE, Davis RE, Chen R, Satlin A, Mates S. Correll CU, et al. Schizophr Res. 2021 Feb;228:198-205. doi: 10.1016/j.schres.2020.12.006. Epub 2021 Jan 13. Schizophr Res. 2021. PMID: 33453691 Free article.

6

Lumateperone (Caplyta) for schizophrenia.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Jul 27;62(1603):113-116. Med Lett Drugs Ther. 2020. PMID: 32728011 Review. No abstract available.

7

Lumateperone: A Novel Antipsychotic for Schizophrenia.

Greenwood J, Acharya RB, Marcellus V, Rey JA. Greenwood J, et al. Ann Pharmacother. 2021 Jan;55(1):98-104. doi: 10.1177/1060028020936597. Epub 2020 Jun 26. Ann Pharmacother. 2021. PMID: 32590907 Review.

8

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.

Correll CU, Davis RE, Weingart M, Saillard J, O'Gorman C, Kane JM, Lieberman JA, Tamminga CA, Mates S, Vanover KE. Correll CU, et al. JAMA Psychiatry. 2020 Apr 1;77(4):349-358. doi: 10.1001/jamapsychiatry.2019.4379. JAMA Psychiatry. 2020. PMID: 31913424 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year